Small Intestinal Bacterial Overgrowth is one of the most prevalent and most mismanaged conditions in integrative gastroenterology. It disrupts digestion at multiple levels simultaneously — impairing enzyme function, hijacking bile acids, damaging the gut lining, and driving malabsorption that conventional testing rarely catches. This article covers the full clinical picture: how SIBO develops, exactly how it sabotages digestive enzyme function, how to test accurately, and what a comprehensive treatment protocol looks like.
What Is SIBO?
The small intestine — spanning approximately 6 meters from the pylorus to the ileocecal valve — is designed to be a relatively low-bacteria environment. Under normal conditions, bacterial counts in the small intestine are kept at 10³–10⁴ colony-forming units per milliliter (CFU/mL), compared to 10¹¹–10¹² CFU/mL in the colon. This differential is maintained by several physiological defense mechanisms: gastric acid, bile salts, intestinal motility, the ileocecal valve, and secretory IgA.
Small Intestinal Bacterial Overgrowth (SIBO) occurs when this balance is disrupted — either through excess bacterial numbers, the presence of colonic-type organisms in the small intestine, or both. The clinical consequence is a fundamentally compromised digestive environment in the organ responsible for virtually all nutrient absorption.
SIBO affects an estimated 10–15% of the general population but is significantly more prevalent — up to 78% — in people with IBS, making it one of the most important diagnoses to rule out in any patient with chronic digestive dysfunction (Pimentel et al., American Journal of Gastroenterology, 2003).
Root Causes: How SIBO Develops
SIBO is not a primary disease — it is always the downstream consequence of one or more failed defense mechanisms:
- Impaired Migrating Motor Complex (MMC): The MMC is a cyclic "housekeeping" wave of intestinal contractions that occurs every 90–120 minutes during fasting, sweeping bacteria, debris, and undigested material from the small intestine into the colon. It is the single most important anti-SIBO mechanism. Anything that disrupts MMC function — chronic stress, PPI use, autonomic neuropathy, post-infectious gut dysmotility, hypothyroidism — creates conditions for bacterial stagnation and overgrowth. Dr. Mark Pimentel, MD, at Cedars-Sinai, has published extensively on the relationship between post-infectious MMC impairment (triggered by anti-vinculin antibodies) and SIBO/IBS-D (Pimentel et al., PLOS ONE, 2015)
- Low stomach acid (hypochlorhydria): Gastric acid is the first line of defense against bacterial colonization of the upper GI tract. When acid is insufficient — due to PPI use, H2 blockers, autoimmune gastritis, aging, or chronic stress — bacteria survive the stomach and establish residence in the small intestine. PPI use has been consistently associated with a 2–8x increased risk of SIBO in multiple studies
- Anatomical abnormalities: Surgical blind loops, strictures, adhesions from prior surgery, and diverticula create stagnant pockets where bacteria accumulate outside the reach of peristalsis
- Dysmotility disorders: Diabetes (autonomic neuropathy), scleroderma, Parkinson's disease, hypothyroidism, and post-viral dysautonomia all impair intestinal transit, creating a slow-transit environment favorable to overgrowth
- Ileocecal valve dysfunction: The ileocecal valve prevents backflow of colonic bacteria into the small intestine. Dysfunction — from prior infection, inflammation, or adhesions — allows colonic species (particularly methane-producing archaea) to colonize the ileum
- Prior antibiotic use: Broad-spectrum antibiotics disrupt the competitive microbiome balance that normally keeps opportunistic species in check, enabling overgrowth of resistant organisms
- Chronic stress & vagal dysfunction: Sympathetic dominance reduces both digestive motility and secretory IgA — two critical anti-SIBO defenses — while simultaneously impairing MMC function
How SIBO Disrupts Enzyme Function & Digestion
SIBO does not simply compete for nutrients — it actively disrupts the digestive machinery at multiple levels:
Bile Acid Deconjugation
Normally, conjugated bile acids (taurine- and glycine-conjugated) emulsify dietary fats in the small intestine, enabling pancreatic lipase to access and break down triglycerides. Bacteria in the small intestine — particularly anaerobes — produce bile salt hydrolase, an enzyme that deconjugates bile acids prematurely. Deconjugated bile acids are:
- Poorly soluble at small intestinal pH — failing to form micelles needed for fat emulsification
- Directly toxic to the intestinal epithelium at elevated concentrations
- Poorly reabsorbed at the terminal ileum, disrupting the enterohepatic circulation and depleting the total bile acid pool
The clinical result is fat malabsorption — steatorrhea, fat-soluble vitamin deficiency, and weight loss — that mimics EPI and is frequently misattributed to it.
Carbohydrate Fermentation & Gas Production
Small intestinal bacteria ferment dietary carbohydrates — particularly FODMAPs, starches, and sugars — before brush border enzymes can complete digestion and absorption. This produces:
- Hydrogen gas (by gram-negative bacteria) — associated with SIBO-D (diarrhea-predominant) and bloating
- Methane gas (by archaea, particularly Methanobrevibacter smithii) — associated with SIBO-C (constipation-predominant) and slowed transit
- Hydrogen sulfide — associated with "rotten egg" flatulence, visceral hypersensitivity, and mucosal damage
Gas production directly competes with enzyme-mediated digestion by accelerating transit (hydrogen) or slowing it (methane), and by producing organic acids that damage the brush border.
Brush Border Enzyme Damage
Bacterial toxins, deconjugated bile acids, and chronic mucosal inflammation damage the microvilli where brush border enzymes (lactase, sucrase-isomaltase, maltase, dipeptidyl peptidase IV) reside. This produces:
- Acquired lactose intolerance — frequently the first sign of SIBO-related brush border damage
- Impaired disaccharide digestion broadly — compounding the fermentation cycle
- Reduced dipeptidase activity — impairing final protein digestion and amino acid absorption
Nutrient Competitive Consumption
- Vitamin B12: Small intestinal bacteria consume cobalamin before it reaches the terminal ileum — producing B12 deficiency independent of intrinsic factor or dietary intake. This is a classic SIBO finding and an important differential in unexplained B12 deficiency
- Iron: Bacteria compete for luminal iron; chronic SIBO contributes to iron-deficiency anemia that does not respond to oral iron supplementation
- Fat-soluble vitamins: Secondary to bile acid deconjugation and fat malabsorption
Intestinal Permeability
Bacterial LPS, organic acids, and deconjugated bile acids damage tight junction proteins, increasing intestinal permeability. This drives systemic inflammation, food sensitivities, and immune dysregulation — creating a vicious cycle in which SIBO and leaky gut perpetuate each other.
Testing for SIBO
- Lactulose breath test (LBT): The most widely available test — measures hydrogen and methane gas in exhaled breath at intervals after ingesting lactulose. Elevated hydrogen at 90 minutes or methane at any point suggests SIBO. Sensitivity varies by protocol — a 3-hour test with both hydrogen and methane measurement improves accuracy
- Glucose breath test (GBT): Uses glucose (absorbed in the proximal small intestine) rather than lactulose — fewer false positives but misses distal SIBO
- Trio-Smart breath test: The most comprehensive available — measures hydrogen, methane, AND hydrogen sulfide, identifying the SIBO variant that standard tests miss (SIBO-S)
- Small intestine aspirate & culture: The gold standard but rarely used in practice — invasive, expensive, and prone to contamination
- Anti-CdtB & anti-vinculin antibodies: Blood test identifying post-infectious IBS/SIBO — elevated antibodies indicate prior food poisoning as the SIBO trigger (Pimentel et al., PLOS ONE, 2015)
Comprehensive Treatment Protocol
Phase 1: Eradication
- Rifaximin (prescription): The first-line pharmaceutical for hydrogen-dominant SIBO — a non-absorbable antibiotic that acts locally in the small intestine with minimal systemic effects. 550mg three times daily for 14 days. A landmark RCT (Pimentel et al., NEJM, 2011) demonstrated 40–55% eradication rates with rifaximin alone in IBS-D
- Rifaximin + Neomycin (for methane-dominant SIBO): Methane-producing archaea require dual therapy — rifaximin plus neomycin (or rifaximin plus metronidazole) for 14 days. Lovaza (high-dose fish oil) has also shown synergistic benefit in methane-dominant SIBO in Pimentel's research
- Herbal antimicrobials (alternative to pharmaceuticals): Combinations of berberine, oregano oil, allicin (from garlic), neem, and Candidia have demonstrated comparable efficacy to rifaximin in a head-to-head study (Chedid et al., Global Advances in Health and Medicine, 2014). Typical protocol: 4 weeks of dual herbal antimicrobial combinations
- Elemental diet: A 2–3 week elemental formula diet (pre-digested amino acids, glucose, MCT oil) starves small intestinal bacteria while maintaining host nutrition — 80–84% eradication rate in Pimentel's original study, higher than antibiotics alone
Phase 2: Restore Motility & Prevent Recurrence
Without restoring the MMC, SIBO recurrence rates are high regardless of eradication success:
- Prokinetics: Low-dose naltrexone (LDN), low-dose erythromycin, prucalopride, or iberogast stimulate MMC activity between meals — the most important anti-recurrence intervention
- Intermittent fasting windows: A minimum 4–5 hour fasting period between meals allows the MMC to complete a full sweep cycle — snacking and grazing suppress MMC function and feed bacterial overgrowth
- Address root cause: HCl restoration, thyroid optimization, PPI discontinuation (where appropriate), stress management — without addressing the upstream driver, recurrence is predictable
Phase 3: Repair & Rebuild
- Digestive enzymes: Broad-spectrum enzymes support digestion during mucosal healing, reducing the undigested substrate available for bacterial fermentation
- L-Glutamine: 5–15g daily to restore intestinal permeability and support enterocyte repair
- Zinc carnosine: Clinically validated for tight junction repair and mucosal integrity restoration
- Vitamin B12 (methylcobalamin): Parenteral or sublingual repletion — oral B12 is unreliable until SIBO is resolved
- Fat-soluble vitamins: Repletion of A, D, E, K in water-soluble or emulsified forms during active malabsorption
- Probiotics (post-eradication): Introduce after eradication — Saccharomyces boulardii, Lactobacillus rhamnosus GG, and spore-based probiotics (Bacillus species) support microbiome restoration without feeding the overgrowth